PT1192131E - Metodo para inibicao da agergacao de proteinas amiloides e para visualizar depositos amiloides utilizando derivados de isoindolina - Google Patents
Metodo para inibicao da agergacao de proteinas amiloides e para visualizar depositos amiloides utilizando derivados de isoindolinaInfo
- Publication number
- PT1192131E PT1192131E PT00938023T PT00938023T PT1192131E PT 1192131 E PT1192131 E PT 1192131E PT 00938023 T PT00938023 T PT 00938023T PT 00938023 T PT00938023 T PT 00938023T PT 1192131 E PT1192131 E PT 1192131E
- Authority
- PT
- Portugal
- Prior art keywords
- inhibiting
- viewing
- protein aggregation
- amyloid deposits
- isoindoline derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13854399P | 1999-06-10 | 1999-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1192131E true PT1192131E (pt) | 2004-11-30 |
Family
ID=22482508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT00938023T PT1192131E (pt) | 1999-06-10 | 2000-05-31 | Metodo para inibicao da agergacao de proteinas amiloides e para visualizar depositos amiloides utilizando derivados de isoindolina |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1192131B1 (pt) |
| JP (1) | JP2003502313A (pt) |
| KR (1) | KR20020012266A (pt) |
| CN (1) | CN1156445C (pt) |
| AP (1) | AP1398A (pt) |
| AT (1) | ATE272623T1 (pt) |
| AU (1) | AU777747B2 (pt) |
| BG (1) | BG106291A (pt) |
| BR (1) | BR0011446A (pt) |
| CA (1) | CA2373394A1 (pt) |
| CR (1) | CR6530A (pt) |
| CZ (1) | CZ20014366A3 (pt) |
| DE (1) | DE60012742T2 (pt) |
| DK (1) | DK1192131T3 (pt) |
| DZ (1) | DZ3262A1 (pt) |
| EA (1) | EA004405B1 (pt) |
| EE (1) | EE200100666A (pt) |
| ES (1) | ES2223531T3 (pt) |
| GE (1) | GEP20043407B (pt) |
| HK (1) | HK1046283B (pt) |
| HR (1) | HRP20020027A2 (pt) |
| HU (1) | HUP0201586A2 (pt) |
| IL (1) | IL146455A0 (pt) |
| IS (1) | IS6162A (pt) |
| MA (1) | MA26807A1 (pt) |
| MX (1) | MXPA01011112A (pt) |
| NO (1) | NO20015992L (pt) |
| NZ (1) | NZ515619A (pt) |
| OA (1) | OA11958A (pt) |
| PL (1) | PL352294A1 (pt) |
| PT (1) | PT1192131E (pt) |
| SI (1) | SI1192131T1 (pt) |
| SK (1) | SK17622001A3 (pt) |
| TR (1) | TR200200257T2 (pt) |
| UA (1) | UA64842C2 (pt) |
| WO (1) | WO2000076969A1 (pt) |
| YU (1) | YU86801A (pt) |
| ZA (1) | ZA200109164B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972287B1 (en) | 1999-06-10 | 2005-12-06 | Pfizer Inc. | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| EP1225886A2 (en) * | 1999-06-10 | 2002-07-31 | Warner-Lambert Company | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
| CA2357450A1 (en) * | 2000-09-29 | 2002-03-29 | Warner-Lambert Company | Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis |
| GB0031302D0 (en) * | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| AR042206A1 (es) * | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| GB2404855A (en) * | 2003-07-07 | 2005-02-16 | Pantherix Ltd | Arylcarboxylic acid derivatives and their therapeutic use |
| AR061623A1 (es) | 2006-06-26 | 2008-09-10 | Novartis Ag | Derivados de acido fenilacetico |
| US20100183513A1 (en) * | 2006-11-24 | 2010-07-22 | Wolfgang Froestl | N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's |
| WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| PT2307381T (pt) * | 2008-06-09 | 2021-03-15 | Univ Muenchen Ludwig Maximilians | Novas drogas para inibir a agregação de proteínas envolvidas em doenças relacionadas com a agregação de proteínas e/ou doenças neurodegenerativas |
| MX2011008335A (es) | 2009-02-06 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Novedosos compuestos heterociclicos biciclicos sustituidos como moduladores de la gamma secretasa. |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| JP5559309B2 (ja) | 2009-05-07 | 2014-07-23 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体 |
| SG177644A1 (en) | 2009-07-15 | 2012-03-29 | Janssen Pharmaceuticals Inc | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| US9079886B2 (en) | 2010-01-15 | 2015-07-14 | Janssen Pharmaceuticals, Inc. | Substituted triazole derivatives as gamma secretase modulators |
| US8987276B2 (en) | 2011-03-24 | 2015-03-24 | Janssen Pharmaceuticals, Inc. | Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| TWI567079B (zh) | 2011-07-15 | 2017-01-21 | 健生醫藥公司 | 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物 |
| BR112014028395B1 (pt) | 2012-05-16 | 2022-02-01 | Janssen Pharmaceuticals, Inc. | Derivados 3,4-di-hidro-2h-pirido[1,2-a]pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer e composição farmacêutica que os compreende |
| CN104918938B (zh) | 2012-12-20 | 2017-08-15 | 詹森药业有限公司 | 新颖的作为γ分泌酶调节剂的三环3，4‑二氢‑2H‑吡啶并[1，2‑a]吡嗪‑1，6‑二酮衍生物 |
| WO2014111457A1 (en) | 2013-01-17 | 2014-07-24 | Janssen Pharmaceutica Nv | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| DK3133068T3 (da) * | 2014-04-14 | 2021-01-11 | Shanghai hengrui pharmaceutical co ltd | Amidderivater og farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og medicinske anvendelser deraf |
| WO2016033436A1 (en) * | 2014-08-29 | 2016-03-03 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
| KR102336926B1 (ko) | 2014-10-06 | 2021-12-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제 |
| WO2017173274A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| PL3519401T3 (pl) | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator mukowiscydozowego przezbłonowego regulatora przewodnictwa, kompozycje farmaceutyczne, sposoby leczenia i proces wytwarzania modulatora |
| CN110267948B (zh) | 2016-12-09 | 2023-12-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法 |
| CN110225753B (zh) * | 2017-01-28 | 2022-12-09 | 金凯(辽宁)生命科技股份有限公司 | 用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法 |
| WO2018227049A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US11517564B2 (en) | 2017-07-17 | 2022-12-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3071278A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| CN109232533A (zh) * | 2017-09-28 | 2019-01-18 | 北京越之康泰生物医药科技有限公司 | 氮杂环类衍生物、其制备方法及其医药用途 |
| IL273831B1 (en) | 2017-10-19 | 2024-06-01 | Vertex Pharma | Crystal forms and preparations of CFTR modulators |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2023283425A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
-
2000
- 2000-05-31 OA OA1200100320A patent/OA11958A/en unknown
- 2000-05-31 ES ES00938023T patent/ES2223531T3/es not_active Expired - Lifetime
- 2000-05-31 HU HU0201586A patent/HUP0201586A2/hu unknown
- 2000-05-31 YU YU86801A patent/YU86801A/sh unknown
- 2000-05-31 PT PT00938023T patent/PT1192131E/pt unknown
- 2000-05-31 GE GE4625A patent/GEP20043407B/en unknown
- 2000-05-31 BR BR0011446-4A patent/BR0011446A/pt not_active IP Right Cessation
- 2000-05-31 EA EA200101133A patent/EA004405B1/ru not_active IP Right Cessation
- 2000-05-31 DZ DZ003262A patent/DZ3262A1/fr active
- 2000-05-31 CZ CZ20014366A patent/CZ20014366A3/cs unknown
- 2000-05-31 JP JP2001503829A patent/JP2003502313A/ja active Pending
- 2000-05-31 KR KR1020017015827A patent/KR20020012266A/ko not_active Application Discontinuation
- 2000-05-31 MX MXPA01011112A patent/MXPA01011112A/es not_active Application Discontinuation
- 2000-05-31 CN CNB008087288A patent/CN1156445C/zh not_active Expired - Fee Related
- 2000-05-31 SI SI200030475T patent/SI1192131T1/xx unknown
- 2000-05-31 NZ NZ515619A patent/NZ515619A/en unknown
- 2000-05-31 AU AU53120/00A patent/AU777747B2/en not_active Ceased
- 2000-05-31 AP APAP/P/2002/002389A patent/AP1398A/en active
- 2000-05-31 AT AT00938023T patent/ATE272623T1/de not_active IP Right Cessation
- 2000-05-31 SK SK1762-2001A patent/SK17622001A3/sk unknown
- 2000-05-31 UA UA2001117664A patent/UA64842C2/uk unknown
- 2000-05-31 EE EEP200100666A patent/EE200100666A/xx unknown
- 2000-05-31 CA CA002373394A patent/CA2373394A1/en not_active Abandoned
- 2000-05-31 PL PL00352294A patent/PL352294A1/xx not_active Application Discontinuation
- 2000-05-31 EP EP00938023A patent/EP1192131B1/en not_active Expired - Lifetime
- 2000-05-31 DE DE2000612742 patent/DE60012742T2/de not_active Expired - Fee Related
- 2000-05-31 TR TR2002/00257T patent/TR200200257T2/xx unknown
- 2000-05-31 DK DK00938023T patent/DK1192131T3/da active
- 2000-05-31 IL IL14645500A patent/IL146455A0/xx unknown
- 2000-05-31 WO PCT/US2000/015073 patent/WO2000076969A1/en not_active Application Discontinuation
-
2001
- 2001-11-06 ZA ZA200109164A patent/ZA200109164B/en unknown
- 2001-11-15 IS IS6162A patent/IS6162A/is unknown
- 2001-12-07 NO NO20015992A patent/NO20015992L/no not_active Application Discontinuation
- 2001-12-07 CR CR6530A patent/CR6530A/es not_active Application Discontinuation
-
2002
- 2002-01-03 MA MA26467A patent/MA26807A1/fr unknown
- 2002-01-09 BG BG106291A patent/BG106291A/bg unknown
- 2002-01-10 HR HR20020027A patent/HRP20020027A2/hr not_active Application Discontinuation
- 2002-10-30 HK HK02107877.1A patent/HK1046283B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1192131E (pt) | Metodo para inibicao da agergacao de proteinas amiloides e para visualizar depositos amiloides utilizando derivados de isoindolina | |
| ID23983A (id) | Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin | |
| NO20016277L (no) | Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger | |
| EE200100358A (et) | Meetod ja komplekt prioonivalgu ekstraheerimiseks | |
| NO20012160L (no) | Anordning for behandling av makuladegenerasjon | |
| ID29089A (id) | Sediaan farmasi moksifloksasin | |
| EE04664B1 (et) | Pulverisaator ja pulverisatsioonimeetod | |
| EE200100673A (et) | Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks | |
| NO20004277L (no) | Indolderivater og farmasøytiske sammensetninger omfattende det samme | |
| PT906092E (pt) | Composicoes farmaceuticas baseadas em diclofenac | |
| NO20011925D0 (no) | Multippel domene glykoproteinhormoner og fremgangsmåter for anvendelse derav | |
| PT1051172E (pt) | Metodo para tratamento da dpco | |
| DE69940319D1 (de) | Amsh protein und dessen cdns | |
| FI990215A (fi) | Menetelmä ja laite nesteen haihduttamiseksi | |
| NO20013303L (no) | Presentasjonsinnretning for matpartier | |
| ES1041923Y (es) | Contenedor perfeccionado para mecanismos electricos y similares. | |
| ES1042757Y (es) | Barbacoa perfeccionada. | |
| ES1041780Y (es) | Vitrina perfeccionada. | |
| ES1039599Y (es) | Dispositivo de cierre perfeccionado para depositos subterraneos. | |
| FI990665A0 (fi) | Menetelmä ja sovitelma sillan siirtämiseksi | |
| ITMO990093A0 (it) | Apparato e metodo per assemblare cassetti. | |
| ES1044939Y (es) | Banderilla perfeccionada de rotula. | |
| ES1043798Y (es) | Barbacoa perfeccionada. | |
| ES1044287Y (es) | Estructura perfeccionada para muebles publicitarios. | |
| ES1041788Y (es) | Expositor sinfin perfeccionado. |